Latest Breaking News On - Irina koffler - Page 9 : comparemela.com

Sol-Gel Technologies Ltd to Host Virtual KOL Event on Gorlin Syndrome and the Upcoming Phase 3 Trial for SGT-610

Event to be held on December 6, 2023 will focus on preventing basal cell carcinomas associated with Gorlin syndrome with a discussion of the disease burden, SGT-610 and the upcoming Phase 3 trial NESS ZIONA, Israel, Nov. 28, 2023 (GLOBE NEWSWIRE) Sol-Gel Technologies, Ltd. (Nasdaq: SLGL) (“Sol-Gel”), a dermatology company leveraging innovative approaches to develop pioneering treatments for patients with severe skin conditions, and with two approved large-category dermatology products, TWYNEO

United statesUnited kingdomUniversity of california san franciscoIsrael generalSan franciscoErvin epsteinIrina kofflerErvin epstein jrGilad mamlokJulie breneiserNational institutes of healthFounder of pellepharm incCompany annual report on formGorlin syndrome allianceHebrew university of jerusalemPeptor ltd

SCYNEXIS Reports Third Quarter 2023 Financial Results and Provides Corporate Update

SCYNEXIS Reports Third Quarter 2023 Financial Results and Provides Corporate Update
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

Triterpenoid antifungalsHansoh pharmaDavid anguloIrina kofflerCongress on trends in medical mycologyExchange commissionPreclinical development programHansoh pharmaceutical group companyScynexis incGlobe newswire scynexis incDrug administrationThird quarterProvides corporateChief executive officerHansoh pharmaceutical group company limitedNew drug application

Tiziana Life Sciences to Present Recent Clinical Updates at BIO-Europe in Munich, Germany, November 6-8, 2023

Tiziana Life Sciences to Present Recent Clinical Updates at BIO-Europe in Munich, Germany, November 6-8, 2023
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Paul spencerMatthew davisIrina kofflerBusiness developmentTiziana life sciencesLifesci advisorsTiziana life sciences ltdLife sciencesChief operating officerChief medical officerTiziana lifeEnable breakthroughsRoom sanInvestor relationsSci advisors

Tiziana Life Sciences Ltd : Tiziana Life Sciences to Present Recent Clinical Updates at BIO-Europe in Munich, Germany, November 6-8, 2023

Tiziana Life Sciences Ltd : Tiziana Life Sciences to Present Recent Clinical Updates at BIO-Europe in Munich, Germany, November 6-8, 2023
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

Matthew davisIrina kofflerPaul spencerTiziana life sciences ltdLifesci advisorsBusiness developmentTiziana life sciencesChief operating officerChief medical officerTiziana lifeEnable breakthroughsRoom sanLife sciencesInvestor relationsSci advisorsIhre watchlist

SCYNEXIS Presents New Preclinical Data on Second Generation Fungerp SCY-247 at the 11th Congress on Trends in Medical Mycology (TIMM)

JERSEY CITY, N.J., Oct. 24, 2023 (GLOBE NEWSWIRE) SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced the presentation of preclinical data on its second generation fungerp candidate, SCY-247, against a broad panel of fungal pathogens. The analyses were presented by Mahmoud Ghannoum, Ph.D, Professor and Director Center for Medical Mycology, Case Western Reserve Universit

Mahmoud ghannoumMartin hoeniglIrina kofflerCase western reserve universityEuropean confederation of medical mycologyScynexis incDrug administrationGlobe newswire scynexis incCongress on trends in medical mycologyDirector centerMedical mycologyOral triterpenoid antifungalVitro activity againstFungal pathogensAthens greece octoberAssociate professor